The Research Center of Polymorphic Drugs (RCPD) was officially established in October 2011. It is the first open scientific research institute specializing in systematic research of polymorphic drugs in China. The RCPD is the earliest team engaged in polymorphic drugs research with professional techniques and rich experience in China. It takes a leading position in the field of polymorphic drugs research in China.
The RCPD has made important contributions to the establishment of a key technology system for chemical polymorphic drugs, the R&D of innovative and generic drugs, quality standards and detection technology. The center has undertaken 70% of professional and technical services related with polymorphic drugs for drug research institutions and pharmaceutical enterprises in China.
The RCPP focuses on polymorphism and co-crystals of pharmaceuticals. The Center is a national third-party testing laboratory, which has the technology and equipment for polymorphic drugs testing, and can issue test reports with the metrology certification CMA logo and the laboratory accreditation CNAS logo.
The aim of the CPP is to promote the R&D of polymorphic drugs in China, improve the research level, and achieve the goal of quality domestic polymorphic drugs in line with international standards.
Main research interests:
1) Key platform construction for solid drugs based on international frontier technologies;
2) Research on new techniques and methods of drug R&D;
3) Research on innovative and generic drugs;
4) Research on metrological standard and certified reference material of drugs;
5) Research on polymorphism and druggability of drugs;
6) Research on new drugs and new indications of pharmaceutical cocrystals.
